Halozyme prices $1.3B convertible notes offering; to repurchase ~$1.02B of existing 2027/2028 notes

HALOZYME THERAPEUTICS, INC.

Priced $650M of 0% convertible notes due 2031 and $650M of 0.875% notes due 2032; initial purchasers have 13-day option for additional $200M.
Initial conversion price of ~$87.20/share, a 27.5% premium over the $68.39 closing price on Nov. 6, 2025.
Net proceeds of ~$1.274B ($1.47B if option exercised); ~$1.019B to repurchase outstanding 0.25% 2027 and 1.00% 2028 notes.
Entered into capped call transactions with cap price of $136.78/share to reduce potential dilution upon conversion.
Expected to close offering on November 12, 2025; remainder of proceeds for general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.